title: Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy.
abstract: OBJECTIVE
  To describe the characteristics of patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy (HAART).
  
  
  METHODS
  Prospective cohort study. Baseline (enrollment) data were compared between patients with newly diagnosed cytomegalovirus retinitis (incident cases) and those with previously diagnosed cytomegalovirus retinitis (prevalent cases).
  
  
  RESULTS
  As of December 31, 2000, 45 incident and 200 prevalent cases had been enrolled. Among prevalent cases, the median time from cytomegalovirus retinitis diagnosis was 2.9 years. Incident cases were more likely than prevalent cases to be women (35.4% vs 15.3%, P =.001), African American (45.4% vs 20.4%, P =.002), and uninsured (29.6% vs 7.6%, P <.001). Incident cases were less likely than prevalent cases to be on HAART (51.2% vs 77.6%, P =.001) and to have had an immunologic response to HAART (increase in CD4(+) T-cell count to > 100 cells/microl) (12.2% vs 57.5%, P <.001). The median CD4(+) T-cell count at enrollment among incident cases was 17 cells/microl and among prevalent cases was 159 cells/microl (P <.001). Immune recovery uveitis had been diagnosed in 15.5% of the prevalent cases. Sixty-three percent of prevalent cases were not on anticytomegalovirus therapy.
  
  
  CONCLUSIONS
  There is a population of patients with previously diagnosed and longstanding cytomegalovirus retinitis who have experienced immune recovery as a consequence of HAART and are no longer receiving anticytomegalovirus therapy. There are demographic differences between incident and prevalent cases that may reflect the evolution of the AIDS epidemic and differences in utilization of health care services.
authors.affiliation: Wilmer Eye Institute, 550 North Broadway, Suite 700, Baltimore, Maryland 21205, USA. djabs@jhmi.edu
authors.forename: Douglas A
authors.initials: DA
authors.lastname: Jabs
authors.forename: Mark L
authors.initials: ML
authors.lastname: Van Natta
authors.forename: John H
authors.initials: JH
authors.lastname: Kempen
authors.forename: Peter
authors.initials: P
authors.lastname: Reed Pavan
authors.forename: Jennifer I
authors.initials: JI
authors.lastname: Lim
authors.forename: Robert L
authors.initials: RL
authors.lastname: Murphy
authors.forename: Larry D
authors.initials: LD
authors.lastname: Hubbard
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000276:immunology; D000293:Adolescent; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D015331:Cohort Studies; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy / Q000453:epidemiology* / Q000276:immunology; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011446:Prospective Studies; D014481:United States / Q000453:epidemiology; D014605:Uveitis / Q000175:diagnosis
chemical_list: D000998:Antiviral Agents